GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Belite Bio Inc (NAS:BLTE) » Definitions » Institutional Ownership

Belite Bio (Belite Bio) Institutional Ownership : 0.08% (As of Jun. 23, 2024)


View and export this data going back to 2022. Start your Free Trial

What is Belite Bio Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Belite Bio's institutional ownership is 0.08%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Belite Bio's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Belite Bio's Float Percentage Of Total Shares Outstanding is 39.80%.


Belite Bio Institutional Ownership Historical Data

The historical data trend for Belite Bio's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Belite Bio Institutional Ownership Chart

Belite Bio Historical Data

The historical data trend for Belite Bio can be seen below:

2023-08-31 2023-09-30 2023-10-31 2023-11-30 2023-12-31 2024-01-31 2024-02-29 2024-03-31 2024-04-30 2024-05-31
Institutional Ownership 0.07 0.10 0.10 0.10 0.10 0.09 0.09 0.09 0.08 0.08

Belite Bio Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Belite Bio (Belite Bio) Business Description

Traded in Other Exchanges
Address
12750 High Bluff Drive, Suite 475, San Diego, CA, USA, 92130
Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively lead to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.